INTRODUCTION

Pain is one of the most feared and distressing symptoms associated with cancer. In Portugal, the incidence of malignant tumors has been increasing regularly, according to the 2017 National Program for Oncological Diseases. In 2016, cancer was the second basic cause of death in Portugal, representing 24.7% of mortality.

Recently, a Portuguese study showed that of 371 patients with cancer-related pain (CRP), 77% had moderate to severe pain, whose severity could be explained by the lower morphine equivalent daily dose prescribed. Moreover, undertreatment of CRP was present in 25.6% of patients. There was an association between inadequacy of CRP treatment and absence of opioid prescriptions ($p < 0.001$).

ACCESS TO ADEQUATE PAIN TREATMENT

Uncontrolled pain is a major public health concern. People with CRP ought to have access to appropriate pain assessment and treatment by adequately trained health care professionals.

The Declaration of Montreal states that access to pain management is a fundamental human right. Withholding pain treatment is profoundly wrong, leading to unnecessary suffering which is harmful.

According to the World Health Organization, in its 2011 guidance document ‘Ensuring balance in national policies on controlled substances’, governments should ensure that all population groups, without discrimination, equally benefit from their policies on the availability and accessibility of controlled medicines for rational medical use. That has been established in Portugal. Some historical milestones confirm that. In 2003, the Directorate-General of Health safeguarded pain as the 5th vital sign and its assessment became mandatory. In 2004, the Portuguese Medical Association approved the ‘Competence in Pain Medicine’ and, in 2013, likewise, a ‘Competence in Palliative Medicine’ was agreed. In 2011, the Portuguese Ministry of Health launched Law 113/2011 announcing that all the consultations at Pain Clinics within the National Health Service were free of charge. In 2013, the National Strategic Pain Prevention and Control Plan was approved. In 2016, the legislation entitled Portaria 331/2016 declared a new list of WHO-step III analgesics, reimbursable up to 90%, to be used in ambulatory patients with CRP. In 2017, the new National Programme for the Prevention and Control of Pain was launched.

OPIOID CONSUMPTION IN PORTUGAL

Opioids are the pillar of the medical management of moderate to severe CRP. Although extremely high rates of use of opioids exist in a few countries, namely in the USA, it should not be regarded as an ubiquitous problem.

Despite overcoming legislative impediments to availability, opioid consumption (OC) in Portugal is ranked among the lowest in western Europe. There is a certain form of morphinophobia in Portugal. Potential causes of undertreatment of CRP, which are attributable to health care providers, are both the fear of prescribing opioids and the lack of knowledge concerning optimal pain management. That was implied in a cross-sectional study aiming at exploring the significance and attitudes concerning the use of morphine, with 412 Portuguese participants (physicians and nurses) working at different settings (four hospitals and 10 community health centers). It showed that ‘morphine’ firstly suggested ‘analgesia’ to only 32.9% of professionals. The reasons for
not using morphine were fear both of legal risks (56.3%) and of adverse side effects, such as somnolence-sedation (30.5%).11

In a nationwide study, which included a representative sample of the Portuguese adult population (5094 participants), the prevalence of OC in chronic pain was 4.37% (95% confidence interval = 3.4 - 5.5), being 10.13% and 4.24% in cancer and non-cancer patients, respectively.9

Strong opioids were prescribed to 0.17% of the patients. Pain severity was significantly associated with OC, however in multivariate modeling only pain-related disability remained associated to OC.9

A Portuguese prospective observational study with 301 advanced cancer patients referred to palliative care showed that 74% were on opioids, 42% had moderate to severe and 35.2% had no pain at all. It found that moderate to severe CRP was associated with shorter time to death.12 Sample characteristics in the latter study were quite different from the ones found in the previously mentioned cross-sectional Portuguese observational study4,5: patients were ambulatory, CRP was present in 100%, 83.3% had good performance status and 88.7% were on opioids, yet more than 2/3 of the sample still had moderate to severe CRP. Prescribed opioids were weak (73.3%), mainly tramadol, and rarely strong ones (15.4%).5 This was odd because firstly, patients were followed at a national cancer center; secondly, because in cancer patients low-dose morphine reduces pain intensity significantly compared with weak opioids, with a similar good tolerability and an earlier effect.13

The role of tramadol is limited in moderate to severe CRP.4

The Pain & Policy Studies Group, a WHO Collaborating Center, receives from the International Narcotics Control Board consumption data for six principal opioids used to treat moderate to severe pain.10 These data represent the amounts of opioids distributed for medical purposes to the ‘retail’ level in a country (i.e., to those institutions and programs that are licensed to dispense to patients, such as hospitals, nursing homes, pharmacies, hospices, palliative care programs, or medication assisted treatment programs).4 It combines OC both for cancer and non-cancer pain, with no distinction between them. Recent data showed that OC in Portugal, not considering methadone use, was 84.27 morphine equivalent (ME).10

For comparison purpose, in 2015, in Portugal, methadone use represented 97.87 ME, much more than other opioids, altogether, prescribed in the country. Methadone is a drug that has similar analgesic benefits to morphine and has a role in the management of CRP in adults. Other opioids such as morphine and fentanyl are more expensive than methadone, but they are far easier to manage.15 It is likely, that much, if not most, of the methadone in Portugal is used for medication assisted treatment of opioid dependence syndrome and, therefore, is not a good indication of a country’s capacity to relieve pain.10

If we look at the global OC in Portugal, we end up with 182.13 ME. This is less than the figures found, excluding methadone, in southern countries like Spain, in western countries like the Netherlands and Switzerland, and in northern countries like Norway and Sweden. All of these have OC ranging from 215 and 265 ME (methadone not considered).10

In 2015, out of 24 European countries analyzed, there were only six with fewer OC (excluding methadone) than Portugal: Croatia, Montenegro, Albania, Estonia, Latvia and Lithuania. All of these have OC less than 39 ME. In the other 17 countries apart from Portugal OC varies from 125 ME (in Ireland) to 517.69 (in Germany). Southern countries like Italy, Greece and Spain have ME of 131.86, 155.31 and 233.58, respectively, all above the OC in Portugal.10

CONCLUSION

Opioid prescribing and CRP: is there an adequate relationship balancing between optimal use of potent analgesics and stable pain management? If you were to find a CRP undertreatment rate of 25.6% – in a sample of cancer patients with metastatic disease (70.9%), on palliative treatment (47.4%), suffering from moderate to severe pain (77%), and dealing with depression (75.5%) and anxiety (70.6%)4,5 – what would you think about? Are we taking the bull by the horns? We sustain: there is still room for improvement.

REFERENCES

9. Azvedo LF, Costa-Pereira A, Mendoça L, Dias CC, Castro-Lopes JM. A population-based study on chronic pain and the use of opioids in...


